138 related articles for article (PubMed ID: 37029039)
21. Financial hardship and psychosocial well-being and quality of life among prostate cancer survivors in the United States.
Yabroff KR; Zhao J; Chen MH; Hoque J; Arias G; Han X; Zheng Z
Urol Oncol; 2023 Sep; 41(9):380-386. PubMed ID: 37202329
[TBL] [Abstract][Full Text] [Related]
22. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
[TBL] [Abstract][Full Text] [Related]
23. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Payne H; Bahl A; Mason M; Troup J; De Bono J
BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
[TBL] [Abstract][Full Text] [Related]
24. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
Tseng CW; Brook RH; Keeler E; Mangione CM
JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
[TBL] [Abstract][Full Text] [Related]
25. Financial toxicity of cancer treatment in India: towards closing the cancer care gap.
Prinja S; Dixit J; Gupta N; Dhankhar A; Kataki AC; Roy PS; Mehra N; Kumar L; Singh A; Malhotra P; Goyal A; Rajsekar K; Krishnamurthy MN; Gupta S
Front Public Health; 2023; 11():1065737. PubMed ID: 37404274
[TBL] [Abstract][Full Text] [Related]
26. Financial toxicity in cancer care: origins, impact, and solutions.
Abrams HR; Durbin S; Huang CX; Johnson SF; Nayak RK; Zahner GJ; Peppercorn J
Transl Behav Med; 2021 Nov; 11(11):2043-2054. PubMed ID: 34850932
[TBL] [Abstract][Full Text] [Related]
27. Predictors of Financial Toxicity Among United States Prostate Cancer Survivors: Results From a National Survey.
Stone BV; Labban M; Filipas DK; Beatrici E; Frego N; Qian ZJ; Voleti SS; Lipsitz SR; Kibel AS; Trinh QD; Cole AP
Urol Pract; 2023 Sep; 10(5):459-466. PubMed ID: 37498685
[TBL] [Abstract][Full Text] [Related]
28. Financial toxicity in prostate cancer survivors: A national cross-sectional assessment of subjective financial burden.
Herrera CD; Guerra CE; Narayan V; Guzzo TJ; Mamtani R; Lee DJ; Tasian GE; Talwar R
Urol Oncol; 2023 Feb; 41(2):105.e1-105.e8. PubMed ID: 36372635
[TBL] [Abstract][Full Text] [Related]
29. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
30. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
31. Financial toxicity and strain among men receiving prostate cancer care in an equal access healthcare system.
Bauer AG; Jefferson M; Nahhas GJ; Savage S; Drake R; Lilly M; Ambrose L; Caulder S; Mahvi D; Hughes Halbert C
Cancer Med; 2020 Dec; 9(23):8765-8771. PubMed ID: 33070458
[TBL] [Abstract][Full Text] [Related]
32. Understanding regional variation in Medicare expenditures for initial episodes of prostate cancer care.
Wang SY; Wang R; Yu JB; Ma X; Xu X; Kim SP; Soulos PR; Saraf A; Gross CP
Med Care; 2014 Aug; 52(8):680-7. PubMed ID: 25023913
[TBL] [Abstract][Full Text] [Related]
33. Delivery of Financial Navigation Services Within National Cancer Institute-Designated Cancer Centers.
de Moor JS; Mollica M; Sampson A; Adjei B; Weaver SJ; Geiger AM; Kramer BS; Grenen E; Miscally M; Ciolino HP
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34222790
[TBL] [Abstract][Full Text] [Related]
34. Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.
Chiong E; Murphy DG; Akaza H; Buchan NC; Chung BH; Kanesvaran R; Khochikar M; Letran J; Lojanapiwat B; Ng CF; Ong T; Pu YS; Saad M; Schubach K; Türkeri L; Umbas R; Le Chuyen V; Williams S; Ye DW; ; Davis ID
BJU Int; 2019 Jan; 123(1):22-34. PubMed ID: 30019467
[TBL] [Abstract][Full Text] [Related]
35. Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis.
Wei Y; Hay JW; Hay AR; Suen SC
BMC Urol; 2022 May; 22(1):76. PubMed ID: 35550071
[TBL] [Abstract][Full Text] [Related]
36. Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims.
Vyas A; Descoteaux A; Kogut S; Parikh MA; Campbell PJ; Green A; Westrich K
J Manag Care Spec Pharm; 2022 Aug; 28(8):831-844. PubMed ID: 35876294
[No Abstract] [Full Text] [Related]
37. The utility of cost discussions between patients with cancer and oncologists.
Zafar SY; Chino F; Ubel PA; Rushing C; Samsa G; Altomare I; Nicolla J; Schrag D; Tulsky JA; Abernethy AP; Peppercorn JM
Am J Manag Care; 2015 Sep; 21(9):607-15. PubMed ID: 26618364
[TBL] [Abstract][Full Text] [Related]
38. Understanding financial toxicity in head and neck cancer survivors.
Mady LJ; Lyu L; Owoc MS; Peddada SD; Thomas TH; Sabik LM; Johnson JT; Nilsen ML
Oral Oncol; 2019 Aug; 95():187-193. PubMed ID: 31345389
[TBL] [Abstract][Full Text] [Related]
39. Financial toxicity assessment and associated factors analysis of patients with cancer in China.
Qiu Z; Yao L; Jiang J
Support Care Cancer; 2023 Apr; 31(5):264. PubMed ID: 37058171
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
